肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2012年
12期
822-824
,共3页
钱露%王侠%杨春华%张艳%徐钰梅%章龙珍
錢露%王俠%楊春華%張豔%徐鈺梅%章龍珍
전로%왕협%양춘화%장염%서옥매%장룡진
子宫颈肿瘤%基因,p53%基因治疗%药物疗法,联合%放射疗法
子宮頸腫瘤%基因,p53%基因治療%藥物療法,聯閤%放射療法
자궁경종류%기인,p53%기인치료%약물요법,연합%방사요법
Uterine cervical neoplasms%Genes,p53%Gene therapy%Drug therapy,combination%Radiotherapy
目的 探讨重组人p53腺病毒(rAd-p53)瘤内注射联合同步放化疗治疗中晚期子宫颈癌患者的近期疗效及安全性.方法 将21例确诊中晚期子宫颈鳞状细胞癌的患者随机分为两组,治疗组(10例)行rAd-p53瘤内注射联合同步放化疗,对照组(11例)仅行同步放化疗,比较两组治疗结束时患者的近期疗效及主要不良反应.结果 治疗组完全缓解(CR)2例,部分缓解(PR)6例,稳定(SD)2例,总有效率80％；对照组PR 3例,SD 6例,进展(PD)2例,总有效率27.3％,治疗组和对照组疗效差异有统计学意义(x2=76.00,P＜0.05),rAd-p53的毒副作用主要是自限性发热,两组骨髓抑制反应的发生率差异无统计学意义(x2=119.50,P＞ 0.05).结论 rAd-p53瘤内注射在中晚期子宫颈癌的同步放化疗中具有增效作用,rAd-p53瘤内注射是安全有效并方便的治疗手段.
目的 探討重組人p53腺病毒(rAd-p53)瘤內註射聯閤同步放化療治療中晚期子宮頸癌患者的近期療效及安全性.方法 將21例確診中晚期子宮頸鱗狀細胞癌的患者隨機分為兩組,治療組(10例)行rAd-p53瘤內註射聯閤同步放化療,對照組(11例)僅行同步放化療,比較兩組治療結束時患者的近期療效及主要不良反應.結果 治療組完全緩解(CR)2例,部分緩解(PR)6例,穩定(SD)2例,總有效率80％；對照組PR 3例,SD 6例,進展(PD)2例,總有效率27.3％,治療組和對照組療效差異有統計學意義(x2=76.00,P＜0.05),rAd-p53的毒副作用主要是自限性髮熱,兩組骨髓抑製反應的髮生率差異無統計學意義(x2=119.50,P＞ 0.05).結論 rAd-p53瘤內註射在中晚期子宮頸癌的同步放化療中具有增效作用,rAd-p53瘤內註射是安全有效併方便的治療手段.
목적 탐토중조인p53선병독(rAd-p53)류내주사연합동보방화료치료중만기자궁경암환자적근기료효급안전성.방법 장21례학진중만기자궁경린상세포암적환자수궤분위량조,치료조(10례)행rAd-p53류내주사연합동보방화료,대조조(11례)부행동보방화료,비교량조치료결속시환자적근기료효급주요불량반응.결과 치료조완전완해(CR)2례,부분완해(PR)6례,은정(SD)2례,총유효솔80％；대조조PR 3례,SD 6례,진전(PD)2례,총유효솔27.3％,치료조화대조조료효차이유통계학의의(x2=76.00,P＜0.05),rAd-p53적독부작용주요시자한성발열,량조골수억제반응적발생솔차이무통계학의의(x2=119.50,P＞ 0.05).결론 rAd-p53류내주사재중만기자궁경암적동보방화료중구유증효작용,rAd-p53류내주사시안전유효병방편적치료수단.
Objective To evaluate the recent clinical efficacy and safety of recombinant human adenovirus-p53 (rAd-p53) combined with radiochemotherapy in treatment for cervical squamocellular cancer (Sqc).Methods 21 patients with cervical squamous cell carcinoma were randomly divided into 2 groups:experiment group (10 patients received treatment with rAd-p53 intratumor injection combined with radiochemotherapy) and control group (12 patients treated with radiochemotherapy alone).The recent efficacy of the two groups were compared at the end of treatment,and major drug toxicity between the two group were compared during the treatment.Results In treatment group,2 cases recieved CR,6 cases PR,2 cases SD,and the rate of total effective was 80.0 ％.In control group,3 cases recieved CR,6 cases SD,2 cases PD,and the rate of total effective was 27.3 ％.The rate of total effective in treatment group is superior to that in control group (x2 =76.00,P ＜ 0.05).The major reaction of rAd-p53 were transient fever after rAd-p53 administration.The two groups of bone marrow inhibition reaction rate with no statistical difference (x2 =119.50,P ＞ 0.05).Conclusion rAd-p53 combined with radiochemotherapy in treatment of advanced cervical squamocellular carcinoma has a synergistic effect.It is a safe,effective and convenient treatment method for rAd-p53 intratumor injection.
